Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose. In the present clinical trial we compared the effects of aspirin (0.5 g given three times a day) and oral-anticoagulant therapy. Of 6908 patients considered for entry, 1303 were randomized to anticoagulant (652) or aspirin (651) an average of 11.4 days after the onset of myocardial infarction and were followed for 6 to 59 months (mean, 29 months). There were 65 deaths in the anticoagulant group and 72 in the aspirin group. The number of patients with reinfarctions was higher in the aspirin group (33 vs. 20). None of these differences were statistically significant. Almost twice as many patients were withdrawn from therapy in the aspirin group. There were 54 per cent more patients with gastrointestinal events in the aspirin group and four times more patients with episodes of severe bleeding in the anticoagulant group. We conclude that aspirin in the dosage used in probably not different from oral anticoagulants in affecting mortality and morbidity after a myocardial infarction. However, this study does not consider the effectiveness of either agent in comparison to no antithrombotic therapy -- an issue that remains unsettled.
This article has been cited by other articles:
Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N.
(2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 257S-298S
[Abstract][Full Text]
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A.
(2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 776S-814S
[Abstract][Full Text]
Husted, S.E., Ziegler, B.K., Kher, A.
(2006). Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J
27: 913-919
[Abstract][Full Text]
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S.
(2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 287S-310S
[Abstract][Full Text]
Harrington, R. A., Becker, R. C., Ezekowitz, M., Meade, T. W., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H.
(2004). Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 513S-548S
[Abstract][Full Text]
Anand, S. S., Yusuf, S.
(2003). Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol
41: 62S-69S
[Abstract][Full Text]
Algra, A., De Schryver, E.L.L.M., van Gijn, J., Kappelle, L.J., Koudstaal, P.J.
(2003). Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin. Stroke
34: 234-235
[Full Text]
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H.
(2002). Warfarin, Aspirin, or Both after Myocardial Infarction. NEJM
347: 969-974
[Abstract][Full Text]
Priori, S.G., Aliot, E., Blomstrom-Lundqvist, C., Bossaert, L., Breithardt, G., Brugada, P., Camm, A.J., Cappato, R., Cobbe, S.M., Di Mario, C., Maron, B.J., McKenna, W.J., Pedersen, A.K., Ravens, U., Schwartz, P.J., Trusz-Gluza, M., Vardas, P., Wellens, H.J.J., Zipes, D.P.
(2001). Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J
22: 1374-1450
Gage, B. F., Fihn, S. D., White, R. H.
(2001). Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation. ANN INTERN MED
134: 465-474
[Abstract][Full Text]
Levine, M. N., Raskob, G., Landefeld, S., Kearon, C.
(2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest
119
: 108S-121S
[Full Text]
Cairns, J. A., Theroux, P., Lewis, H. D. Jr., Ezekowitz, M., Meade, T. W.
(2001). Antithrombotic Agents in Coronary Artery Disease. Chest
119
: 228S-252S
[Full Text]
Altman, R., Rouvier, J., Scazziota, A.
(2000). State-of-the-Art Review : Secondary Prevention of Myocardial Infarction: Beneficial Effect of Combining Oral Anticoagulant Plus Aspirin: Therapy Based on Evidence. CLIN APPL THROMB HEMOST
6: 126-134
Cokkinos, D. V., Toutouzas, P. K.
(1999). Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS). Eur J Heart Fail
1: 419-423
[Abstract][Full Text]
Anand, S. S., Yusuf, S.
(1999). Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis. JAMA
282: 2058-2067
[Abstract][Full Text]
Gorter, J. W.
(1999). Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Neurology
53: 1319-1319
[Abstract][Full Text]
Slater, J. P., Rose, E. A., Levin, H. R., Frazier, O. H., Roberts, J. K., Weinberg, A. D., Oz, M. C.
(1996). Low Thromboembolic Risk Without Anticoagulation Using Advanced-Design Left Ventricular Assist Devices. Ann. Thorac. Surg.
62: 1321-1327
[Abstract][Full Text]
Hart, R. G., Boop, B. S., Anderson, D. C.
(1995). Oral Anticoagulants and Intracranial Hemorrhage : Facts and Hypotheses. Stroke
26: 1471-1477
[Abstract][Full Text]
Cairns, J. A., Markham, B. A.
(1995). Economics and Efficacy in Choosing Oral Anticoagulants or Aspirin After Myocardial Infarction. JAMA
273: 965-967
[Abstract]
Flapan, A D
(1994). Fortnightly Review: Management of patients after their first myocardial infarction. BMJ
309: 1129-1134
[Full Text]
Antiplatelet Trialists,
(1994). Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ
308: 81-106
[Abstract][Full Text]
